EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Randomized controlled trial of the glycine transporter 1 inhibitor PF-03463275 to enhance cognitive training and neuroplasticity in schizophrenia

Toral S Surti, Mohini Ranganathan, Jason K Johannesen, Ralitza Gueorguieva, Emma Deaso, Joshua G Kenney, John H Krystal, Deepak Cyril D'Souza

Schizophrenia Research · 2023-06 · 256 · 36-43

DOI: 10.1016/j.schres.2023.04.010 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Schizophrenia Research, 2023-06. Verfasst von Toral S Surti und 7 weiteren Autor:innen. Beteiligte Einrichtung: Schizophrenia and Neuropharmacology Research Group, VA Connecticut Healthcare System, West Haven, CT, United States of America; Abraham Ribicoff Rese…. Hauptthemen laut MEDLINE: Schizophrenia, Antipsychotic Agents. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCRR NIH HHS, NCATS NIH HHS, NIAAA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

N-methyl-d-aspartate glutamate receptor (NMDAR) hypofunction is implicated in the impaired neuroplasticity and cognitive impairments associated with schizophrenia (CIAS). We hypothesized that enhancing NMDAR function by inhibiting the glycine transporter-1 (GLYT1) would improve neuroplasticity and thereby augment benefits of non-pharmacological cognitive training (CT) strategies. This study examined whether co-administration of a GLYT1 inhibitor and computerized CT would have synergistic effects on CIAS. Stable outpatients with schizophrenia participated in this double-blind, placebo-controlled, within-subject, crossover augmentation study. Participants received placebo or GLYT1 inhibitor (PF-03463275) for two 5-week periods separated by 2 weeks of washout. PF-03463275 doses (40 or 60 mg twice daily) were selected to produce high GLYT1 occupancy. To limit pharmacodynamic variability, only cytochrome P450 2D6 extensive metabolizers were included. Medication adherence was confirmed daily. Participants received 4 weeks of CT in each treatment period. Cognitive performance (MATRICS Consensus Cognitive Battery) and psychotic symptoms (Positive and Negative Syndrome Scale) were assessed in each period. 71 participants were randomized. PF-03463275 in combination with CT was feasible, safe, and well-tolerated at the doses prescribed but did not produce greater improvement in CIAS compared to CT alone. PF-03463275 was not associated with improved CT learning parameters. Participation in CT was associated with improvement in MCCB scores.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SchizophreniaAntipsychotic AgentsHumansGlycine Plasma Membrane Transport ProteinsCognitive TrainingNeuronal PlasticityDouble-Blind MethodImidazolesAzabicyclo Compounds

Stichwörter der Autor:innen

CognitionGlycine transporterNMDAPsychosisRemediationSchizophrenia

Substanzen

Glycine Plasma Membrane Transport ProteinsAntipsychotic Agents1-methyl-1H-imidazole-4-carboxylic acid (3-chloro-4-fluoro-benzyl)-(3-methyl-3-aza-bicyclo(3.1.0) hex-6-ylmethyl)amideImidazolesAzabicyclo Compounds

Autor:innen und Institutionen

  • Schizophrenia and Neuropharmacology Research Group, VA Connecticut Healthcare System, West Haven, CT, United States of America; Abraham Ribicoff Research Facilities, Connecticut Mental Health Center, New Haven, CT, Unit…
  • Department of Psychiatry, Yale University School of Medicine, New Haven, CT, United States of America.

Förderung

  • NCRR NIH HHS
  • NCATS NIH HHS
  • NIAAA NIH HHS
  • National Center for Advancing Translational Sciences
  • National Institute on Alcohol Abuse and Alcoholism
  • U.S. Department of Veterans Affairs
  • Yale Center for Clinical Investigation, Yale School of Medicine
  • Pfizer Pharmaceuticals

Zitieren

APA

Surti, T. S., Ranganathan, M., Johannesen, J. K., Gueorguieva, R., Deaso, E., Kenney, J. G., Krystal, J. H., & D'Souza, D. C. (2023). Randomized controlled trial of the glycine transporter 1 inhibitor PF-03463275 to enhance cognitive training and neuroplasticity in schizophrenia. Schizophrenia Research, 256, 36-43. https://doi.org/10.1016/j.schres.2023.04.010

Vancouver

Surti TS, Ranganathan M, Johannesen JK, Gueorguieva R, Deaso E, Kenney JG, et al. Randomized controlled trial of the glycine transporter 1 inhibitor PF-03463275 to enhance cognitive training and neuroplasticity in schizophrenia. Schizophrenia Research. 2023;256:36-43. doi:10.1016/j.schres.2023.04.010

BibTeX
@article{Surti2023,
  author = {Surti, Toral S and Ranganathan, Mohini and Johannesen, Jason K and Gueorguieva, Ralitza and Deaso, Emma and Kenney, Joshua G and Krystal, John H and D'Souza, Deepak Cyril},
  title = {Randomized controlled trial of the glycine transporter 1 inhibitor PF-03463275 to enhance cognitive training and neuroplasticity in schizophrenia},
  journal = {Schizophrenia Research},
  year = {2023},
  volume = {256},
  pages = {36--43},
  doi = {10.1016/j.schres.2023.04.010}
}
Kostenlos starten →